http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
김제학(Je Hak Kim),김현수(Hyun Su Kim),김영훈(Young Hoon Kim),정성목(Seong Mok Jeong),신재규(Jae Kyu Shin),최재묵(Jae Mook Choi),고형곤(Hyung Kon Ko) 한국응용약물학회 1997 Biomolecules & Therapeutics(구 응용약물학회지) Vol.5 No.3
CJ-50001 is a recombinant granulocyte-colony stimulating factor (rG-CSF) synthesized by recombinant DNA technology using E. coli as an expression system. The general pharmacological properties of CJ50001 were evaluated in mice, rats, dogs and isolated guinea pig ileum. The doses are 100, 300 and 1,000 ㎍/㎏, i.v. for mice and rats, 1, 10 and 100 ㎍/㎏, i.v. for dogs and 1 and 10㎍/ml for isolated guinea pig ileum. Intravenous administration of CJ-50001 at this dose range did not affect general behavior, central nervous system, smooth muscles, gastrointestinal system, cardiovascular and respiratory system and water and electrolytes excretion. In summary, CJ-50001 had no harmful pharmacological effect in these studies even up to the 200-fold expected clinical dose, 250 ㎍/man.
CJ-50001 (rG-CSF) 의 골수이식모델 마우스에 대한 호중구수 회복 촉진효과
김제학(Je Hak Kim),김현수(Hyun Su Kim),김달현(Dal Hyun Kim),임동문(Dong Moon Lim),조효진(Hyo Jin Cho),김종호(Jong Ho Kim),고형곤(Hyung Kon Ko) 한국응용약물학회 1997 Biomolecules & Therapeutics(구 응용약물학회지) Vol.5 No.4
The peripheral neutrophil recovery test was conducted to determine the efficacy of CJ-50001, a drug developed in Cheil Jedang R&D center as a recombinant granulocyte-colony stimulating factor (rG-CSF). Grasin was used as control drug. CJ-50001 and Grasin were subcutaneously administered to γ-ray irradiated mice for 21 days at a dose of 10 ㎍/kg after bone marrow transplantation and the recovery of neutrophil number was examined on the days of 9, 13, 17, and 21 after the drug administration. It was observed that the peripheral neutrophil number of the vehicle control group was recovered to the normal level on the day of 13 after the transplantation whereas the group administered with CJ-50001 and Grasin respectively, showed the normal level of peripheral neutrophil number on 9th day after the bone marrow transplantation. The number of peripheral neutrophils reached the highest level on the 21st day of drug administration, and was recovered to the normal level on the 4th day after ceasing of the drug administration (on the 25th day of the transplantation). Thus, it was presumed that CJ-50001 showed efficacy similar to Grasin on the peripheral neutrophil recovery after bone marrow transplantation.
마우스에서 항암제 유발 호중구감소에 대한 CJ-50001 의 회복촉진효과
김제학(Je Hak Kim),김현수(Hyun Su Kim),백남진(Nam Jin Baek),김달현(Dal Hyun Kim),최재묵(Jae Mook Choi),강재구(Jae Ku Kang),김기완(Ki Wan Kim) 한국응용약물학회 1997 Biomolecules & Therapeutics(구 응용약물학회지) Vol.5 No.4
Neutropenia is a major dose-limiting side effect of cancer chemotherapy. The therapeutic effects of CJ-50001 were examined on neutropenia caused by anticancer agents. Neutropenia was induced by cyclophosphomide (130 mg/kg), doxorubicin (4.5 mg/kg), and vincristine (1 mg/kg) in normal ICR mice and by cyclophosphamide (200 mg/kg) in CT26 adenocarcinoma bearing BALB/C mice. After the subcutaneous injection of anticancer agents, we administered subcutaneously recombinant human granulocyte-colonystimulating factor (100 ㎍/kg/day) to mice in order to stimulate neutrophil production. In normal and tumor-bearing mice, neutrophil production efficacy of CJ-50001 (rG-CSF) was similar to that of Grasin. These results suggest that CJ-50001 could be effective in its clinical use for neutropenia treatment.
정상 ICR mouse 및 SD rat 에서 CJ-50001 (rG-CSF) 의 단회투여후 말초호중구수의 변동 및 용량상관성
김제학(Je Hak Kim),김현수(Hyun Su Kim),김달현(Dal Hyun Kim),임동문(Dong Moon Lim),조효진(Hyo Jin Cho),이현수(Hyun Soo Lee) 한국응용약물학회 1997 Biomolecules & Therapeutics(구 응용약물학회지) Vol.5 No.4
CJ-50001 is a recombinant granulocyte-colony stimulating factor (rG-CSF) developed by Cheil Jedang R&D Center. The effects of CJ-50001 on the increase of peripheral neutrophil count following intravenous and subcutaneous single administration at a dose of 20 ㎍/kg in normal ICR mice and SD rats, respectively, were compared with those of Grasin, a control drug. Both CJ-50001 and Grasin significantly increased the peripheral neutrophil number in four treatment groups and the maximum number of neutrophil was achieved at 12 to 18 h in rats and mice, respectively. The dose dependency test was studied for CJ-50001 only in normal mice by intravenous or subcutaneous administration. When administered i.v or s.c at the various doses in normal mice, CJ-50001 significantly increased the neutrophil number over the dose of 160 ng/kg, compared with the vehicle control group. From these results, it was concluded that CJ-50001 showed efficacy similar to Grasin in the peripheral neutrophil count increase.
유전자 재조합 B 형 간염 바이러스 표면 항원 , CJC-50100 의 일반약리작용
정성학(Seong Hak Jeong),최재묵(Jae Mook Choi),이남중(Nam Jung Lee),전형수(Hyung Soo Jeon),김연희(Yon Hee Kim),김재승(Jae Seung Kim),하석훈(Suk Hoon Ha),김영훈(Young Hoon Kim),이나경(Na Gyung Lee),김제학(Je Hak Kim),박완제(Wan Je Park 한국응용약물학회 2001 Biomolecules & Therapeutics(구 응용약물학회지) Vol.9 No.1
N/A CJC-50100 is a recombinant hepatitis B virus surface antigen (HBsAg) expressed in yeast. The general pharmacological properties of CJC-50100 were evaluated in mice, rats, dogs and isolated guinea pig ileum. The doses were 0.33∼33.3 ㎍/㎏ i.m. for mice and rats and 3.3∼9.9 ㎍/㎏ i.v. for dogs. The concentrations of 0.002∼0.02 ㎍/mlwere used for the assay with guinea pig ileum. Intramuscular administration of CJC-50100 at the doses did not alter general behavior and the responses for central nervous system, smooth muscle, gastrointestinal system, cardiovascular and respiratory system, and water and electrolytes excretion. In summary, CJC-50100 had no pharmacological effect in these studies even up to the 100-fold of the expected clinical dose, 20 ㎍/man/60 kg.
마우스에서 CFC-101 ( 녹농균 백신 ) 의 감염 방어효과
김영지(Young Gi Kim),김제학(Je Hak Kim),박완제(Wan Je Park),안동호(Dong Ho Ahn),홍광희(Kwang Hee Hong),김현수(Hyun Su Kim),김유삼(Yu Sam Kim),함경수(Kyung Soo Hahm) 한국응용약물학회 1994 Biomolecules & Therapeutics(구 응용약물학회지) Vol.2 No.4
To optimize the immunological efficacy of CFC-101, an outer-membrane protein vaccine purified from relatively less pathogenic 4 different Pseudomonas aeruginosa strains, we investigated to establish its dose, administration route, interval and frequency of vaccination in mice. As expected, the 4 CFC-101 producing strains were less pathogenic than the challenging organism, P. aeruginosa GN11189. CFC-101 completely protected the death caused by P. aeruginosa at above 0.05 mg/kg vaccinized by 3 times with 7-day intervals. At the optimally effective dose of 0.2 mg/kg of CFC-101, at least 3 immunizations were necessary for complete protection against P. aeruginosa-induced death. If immunized 3 times, the immunization interval could be shortened up to 2 days to acquire the best protection against P. aeruginosa. CFC-101 was effective either by intraperitoneal, subcutaneous or intramuscular but not by oral administration. The present results show that the newly developed Pseudomonas vaccine, CFC-101, is highly effective for the protection from death caused by pseudomonal infections.
섬수 ( Bufonis Venenum ) 추출물의 약리작용
김영춘(Young Hoon Kim),정성학(Seong Hak Jeong),김종호(Jong Ho Kim),최재묵(Jae Mook Choi),지준환(Joon Hwan Ji),강재구(Jae Koo Kang),박종구(Jong Koo Park),김제학(Je Hak Kim),조희재(Hi Jae Cho) 한국응용약물학회 2001 Biomolecules & Therapeutics(구 응용약물학회지) Vol.9 No.1
N/A Bufonis Venenum is a toad venom and its main components are bufadienolides, namely resibufogenin, bufalin and cinobufagin. The desensitizing effect of Bufonis Venenum is useful for the treatment of the premature ejaculation in Chinese medicine. But, minor components of Bufonis Venenum cause problems such as topical burning, pain, and erectile dysfunction. To clarify and eliminate the components responsible for these side effects, we prepared two extracts of Bufonis Venenum with either 70% ethanol or ethylacetate and tested their pharmacological effects. The extract of Bufonis Venenum with 70% ethanol produced pain response in rat hind paw, and exhibited contraction of rabbit corpus cavernosal muscle in vitro. On the other hand, the ethylacetate extract did not cause pain and smooth muscle contraction. The desensitizing effect of the ethylacetate extract was similar to that of the 70% ethanol extract. In conclusion, these results show that the extract of Bufonis Venenum with ethylacetate does not have the components causing side effects and deserve further study for therapeutic potential in premature ejaculation in men.
CFC-101 ( 녹농균 백신 ) 의 능동 및 수동면역 효과
김영지(Young Gi Kim),김제학(Je Hak Kim),박완제(Wan Je Park),김유삼(Yu Sam Kim),함경수(Kyung Soo Hahm),조양제(Yang Je cho),박관하(Kwan Ha Park) 한국응용약물학회 1994 Biomolecules & Therapeutics(구 응용약물학회지) Vol.2 No.4
The treatment of pseudomonal infection is a perplexed problem because of its modest susceptibility to most of the major antibiotics. A novel Pseudomonas vaccine(CFC-101) was prepared from the outer membrane protein fractions of several Pseudomonas strains. In this study, we examined CFC-101`s effectiveness in both active and passive immunization models. CFC-101 in mice at 0.2 mg/kg, i.p., given three times at two-day intervals, completely prevented the death caused by Pseudomonas aeruginosa. Antibody titer, in accordance with the protective effect in this active immunization, was elevated to its peak level following three consecutive administrations of CFC-101. Thereafter, antibody titer stayed at a constantly high level. Each outer membrane protein fraction from the four CFC-101 producers, exhibited good cross-protective effects in mouse infection models against different Fisher types of P. aeruginosa. In the passive immunization model, 21∼336 ㎍/㎏ of anti-rabbit IgG to CFC-101, when mice being infected with a challenge strain, prevented the Pseudomonas-induced death up to 60%. Therefore, the preventive effect of CFC-101 was verified in both the active and passive immunization models.